For the millions of adults navigating a cancer diagnosis or monitoring emerging oncology options, checkpoint inhibitor therapy has become one of the most consequential shifts in treatment philosophy in decades. Envafolimab represents a structurally distinct entry into that space — one whose subcutaneous delivery format and single-domain antibody design may matter as much as its mechanism.

This review in Frontiers in Immunology synthesizes the emerging clinical evidence around envafolimab, a PD-L1-targeting nanobody currently in clinical evaluation for solid tumors. Unlike conventional monoclonal antibodies such as nivolumab or pembrolizumab, envafolimab is derived from a camelid single-domain antibody scaffold, giving it a markedly smaller molecular footprint. This structural difference enables subcutaneous self-injection rather than intravenous infusion — a logistical distinction with real-world implications for treatment burden. The review also examines combination strategies, exploring how pairing envafolimab with chemotherapy, anti-VEGF agents, or other immunomodulators may address the persistent challenge of primary and acquired resistance. Personalized approaches incorporating tumor mutational burden, microbiome composition, and immune cell profiling are discussed as potential levers for improving durable response rates.

Positioning envafolimab within the broader checkpoint inhibitor landscape requires acknowledging that the PD-1/PD-L1 class is already crowded with well-characterized agents with extensive Phase III data. What distinguishes envafolimab at this stage is its format and flexibility, not yet a demonstrated superiority in efficacy. The clinical trial data referenced remains largely early-phase, limiting conclusions about long-term outcomes or comparative effectiveness. The microbiome and genetic personalization angles, while conceptually compelling, are still largely investigational across all PD-L1 therapies. This review is best read as a useful synthesis of mechanistic rationale and trial-stage evidence — incremental and cataloguing rather than paradigm-shifting — but valuable for clinicians and informed patients tracking where next-generation checkpoint inhibition may be heading.